AVIR
Atea Pharmaceuticals, Inc.Company with tickers: AVIR
CIK
1593899
CUSIP
04683R106
Shares Outstanding
80,027,099
Website
https://www.ateapharma.com
Investor Relations
https://ateapharma.com/
13F Activity (30d)
2 filings
1 filers
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2024-12-10 | Franklin Berger | Lead Independent Director | 359,606 | 2024-12-10 | J.P. Morgan Securities LLC |
| 2024-09-19 | JPM Partners LLC | Affiliate | 1,841 | 2024-09-19 | UBS Financial Services Inc. |
| 2024-09-18 | JPM Partners LLC | Affiliate | 22,187 | 2024-09-18 | UBS Financial Services Inc. |
| 2024-09-17 | JPM Partners LLC | Affiliate | 33,941 | 2024-09-17 | UBS Financial Services Inc. |
| 2024-06-20 | Polsky Bruce | Director | 17,544 | 2024-06-20 | MORGAN STANLEY SMITH BARNEY LLC EXECUTIVE SERVICES |
| 2024-06-05 | JPM Partners LLC | Affiliate | 1,006 | 2024-06-05 | UBS Financial Services Inc. |
| 2024-02-01 | Jean-Pierre Sommadossi | President, CEO, and Chairman | 65,476 | 2024-02-01 | Morgan Stanley |
| 2024-02-01 | Wayne Foster | EVP, Chief Accounting Officer | 14,311 | 2024-02-01 | Morgan Stanley |
| 2024-02-01 | Maria Arantxa Horga | Chief Medical Officer | 18,227 | 2024-02-01 | Morgan Stanley |
| 2024-02-01 | John Vavricka | Chief Commercial Officer | 13,552 | 2024-02-01 | Morgan Stanley |
| 2024-02-01 | Janet MJ Hammond | Chief Development Officer | 16,110 | 2024-02-01 | Morgan Stanley |
| 2024-02-01 | Andrea Corcoran | CFO, EVP, Legal and Secretary | 18,198 | 2024-02-01 | Morgan Stanley |
Showing 1–12 of 12 filings